PROTACs work differently from conventional drugs that merely inhibit a protein’s activity. A typical PROTAC is a bifunctional molecule with one end that binds to a disease-associated protein and another that recruits an E3 ubiquitin ligase, part of the cell’s protein-disposal machinery. By bringing the target protein and the ligase into close proximity, the PROTAC causes the target to be tagged with ubiquitin molecules. The proteasome, a large intracellular complex that degrades ubiquitinated proteins, then dismantles the marked protein. Because a PROTAC can act catalytically—detaching after the target is destroyed and potentially engaging another copy—it may eliminate proteins rather than temporarily blocking them. That promise has attracted intense interest in oncology, where many disease-driving proteins have proved difficult to inhibit with traditional small molecules.

The same molecular features that make PROTACs powerful can also make them difficult to deliver. Many are relatively large and chemically complex, occupying what medicinal chemists call “beyond rule-of-five” space. Their size and polarity can reduce passive diffusion through the lipid bilayer of a cell membrane, while their hydrophobicity can limit water solubility and cause unfavorable distribution in the body. A PROTAC circulating in the bloodstream must reach a tumor, cross or enter cancer cells, escape destructive clearance pathways and arrive in the correct intracellular compartment before it can assemble the molecular interactions needed for protein degradation. Poor membrane permeability and inadequate tumor distribution therefore represent major barriers between promising laboratory chemistry and a practical medicine.

The researchers addressed these problems by attaching a hydrophobic PROTAC called MZ1 to a hydrophilic affibody known as Z_HER2:342. MZ1 is designed to degrade bromodomain-containing protein 4, or BRD4, while the affibody is an engineered affinity protein that recognizes human epidermal growth factor receptor 2, commonly called HER2. Affibodies are small, engineered binding proteins derived from an alpha-helical bacterial receptor domain. Unlike full-size antibodies, they are compact and can be produced and chemically modified as defined molecules. Z_HER2:342 supplies the targeting function, while MZ1 supplies the protein-degradation function. The two components were connected by a linker containing a disulfide bond, creating an amphiphilic conjugate with one water-compatible region and one water-avoiding region.

When placed in water, the conjugates spontaneously organized into nanoparticles, a process known as self-assembly. Amphiphilic molecules can form nanoscale structures because their hydrophilic and hydrophobic sections seek different environments: the water-compatible affibody portions remain exposed to the surrounding liquid, while the hydrophobic MZ1 portions cluster away from it. This arrangement allows the drug molecules to be carried in a compact, water-dispersible form without requiring a separate polymeric carrier or lipid shell. The resulting formulation, called the Z_HER2:342-MZ1 affibody-PROTAC conjugate nanomedicine, was intended to solve two delivery problems at once—keeping MZ1 dispersed in the bloodstream and displaying the HER2-binding affibody on the nanoparticle surface.

The targeting mechanism depends on the abundance of HER2 on the surface of selected cancer cells. HER2 is a receptor tyrosine kinase involved in signaling pathways that regulate proliferation, survival and differentiation. In some breast, ovarian and other cancers, the receptor is produced at unusually high levels, creating a molecular marker that can distinguish malignant cells from many normal tissues. According to the study, the nanoparticles used HER2 receptor-mediated endocytosis to gain entry into cancer cells. In this process, binding at the cell surface triggers the membrane to fold inward and form an intracellular vesicle containing the bound material. The researchers reported effective accumulation and internalization of the conjugate in HER2-positive cancer cells in vitro, consistent with the idea that affibody-mediated recognition improved delivery beyond what free MZ1 could achieve.

The disulfide linker was designed to respond to the reducing conditions inside cells. Glutathione, or GSH, is a major intracellular antioxidant and is generally present at higher concentrations within cells than in the extracellular space or bloodstream. Its thiol group can participate in reduction reactions that cleave disulfide bonds. In the proposed system, intracellular GSH breaks the linker connecting the affibody and MZ1, releasing the PROTAC after the nanoparticle has been internalized. This is a form of chemically triggered release: the carrier remains comparatively stable during circulation but becomes labile in a cellular environment rich in reducing agents. Once liberated, MZ1 can interact with BRD4 and recruit the ubiquitin-proteasome system, converting the delivery event into targeted destruction of an intracellular protein.

BRD4 belongs to the bromodomain and extraterminal, or BET, family of epigenetic reader proteins. Rather than acting as a conventional DNA-binding transcription factor, BRD4 recognizes acetylated lysine residues on histones and other proteins, helping organize transcriptional machinery at active genes. It is particularly associated with regulatory regions such as enhancers and super-enhancers, where it can support expression programs that sustain cancer-cell proliferation and survival. Degrading BRD4 can therefore disrupt multiple transcriptional networks at once. The study reported that the released MZ1 produced BRD4 deficiency and subsequently induced apoptosis, the regulated form of cell death. This mechanism is distinct from simply slowing an enzyme: it removes an entire protein platform that cancer cells may depend on for maintaining gene expression.

The researchers then evaluated the conjugate in vivo after administration through the tail vein in mice carrying HER2-positive SKOV-3 tumors. Intravenous delivery places the formulation directly into the circulation, where its size, surface properties and targeting ligand influence how long it remains in the blood and where it accumulates. The study reported outstanding tumor-specific targeting, increased drug accumulation, enhanced BRD4 degradation and improved antitumor efficacy compared with relevant controls. These findings suggest that the nanoparticles retained their targeting function in the complex environment of an animal and that sufficient MZ1 reached tumor cells to engage its intracellular mechanism. The results also support the value of combining receptor-mediated uptake with a redox-sensitive release step, rather than relying solely on passive nanoparticle accumulation in tumors.

The work does not yet establish whether the platform is safe or effective in people. Mouse tumors do not reproduce the full biological diversity of human cancers, and HER2 expression can vary between tumors and even between cells within the same tumor. The distribution, metabolism and elimination of affibody-based nanoparticles will also need to be characterized in detail, as will possible immune responses, off-target BRD4 degradation and toxicity in healthy tissues. In addition, a clinical formulation would have to meet demanding requirements for manufacturing consistency, stability and dose control. Even so, the study points toward a versatile strategy: a compact targeting protein, a cleavable chemical linker and a self-assembling PROTAC payload are integrated into one molecule that builds its own nanomedicine. If the design can be optimized and validated in more advanced models, it could help turn targeted protein degradation from a promising intracellular concept into a more precise way of delivering cancer therapy.

The idea addresses a growing complication in oncology. Tumors can contain bacteria that are physically sheltered from conventional antibiotics and may alter the biology of surrounding cells. Some tumor-associated microbes can stimulate inflammatory signaling, interfere with immune surveillance or affect how drugs are metabolized. F. nucleatum, best known for its role in oral disease and colorectal cancer, has also been detected in breast tumors. Previous studies cited by the researchers have linked the bacterium to faster tumor growth and metastatic progression in breast cancer models. Intratumoral bacteria may also reduce chemotherapy efficacy by changing the local chemical environment or by promoting signals that help cancer cells survive. Yet most cancer drugs are designed to target tumor cells, while most antibiotics are administered systemically and are not optimized to reach bacteria embedded inside a solid tumor.

The new formulation uses a micelle, a nanoscopic structure assembled from molecules with both water-attracting and water-repelling components. In aqueous biological fluids, the hydrophobic portions cluster inward, forming a core that can solubilize poorly water-soluble compounds, while the hydrophilic polymer chains extend outward and stabilize the particle in water. Paclitaxel is highly hydrophobic and has limited water solubility, a property that complicates its formulation and distribution. By placing it inside the micelle core, POx can carry a high drug payload without relying on the same solvent systems used in some conventional formulations. The outer polymer layer helps the particles remain dispersed under physiological conditions, potentially allowing them to circulate and reach tumors through the abnormal blood vessels associated with solid cancers.

Metronidazole benzoate, the second cargo, is a derivative of metronidazole used to treat infections caused by anaerobic microorganisms. F. nucleatum is an anaerobic bacterium, meaning that it thrives in environments with little or no oxygen—conditions that can occur in poorly perfused regions of tumors. Once metronidazole-related compounds enter susceptible bacteria, their nitro group can be chemically reduced by microbial electron-transfer proteins. The resulting reactive intermediates damage DNA and other essential cellular components, ultimately killing the organism. The tumor environment therefore presents an unusual convergence of targets: paclitaxel disrupts the microtubule system required for cancer-cell division, while metronidazole benzoate is activated in anaerobic microbes. Packaging both agents in the same carrier could synchronize their delivery to a shared pathological site.

Paclitaxel works primarily by binding to tubulin, the protein subunit of microtubules. Rather than allowing microtubules to disassemble normally during cell division, the drug stabilizes them and prevents the dynamic rearrangements needed for chromosome segregation. Cells exposed to paclitaxel can become arrested in mitosis and eventually undergo cell death. Triple-negative breast cancer is a particularly important setting for this strategy because these tumors lack expression of estrogen receptors, progesterone receptors and HER2, limiting the usefulness of several targeted treatments. Chemotherapy remains a major component of treatment, but resistance and relapse are persistent problems. If bacteria in the tumor contribute to inflammatory or survival pathways, eliminating them at the same time as cancer cells could, in principle, remove one source of therapeutic resistance—although that possibility remains to be demonstrated in clinical studies.

The researchers report that the POx micelles containing paclitaxel and metronidazole benzoate formed monodisperse populations, meaning that the particles were relatively uniform in size rather than appearing as a mixture of widely different structures. Uniformity matters because particle size and morphology influence circulation, tissue penetration, drug release and uptake by cells. The formulation also showed high loading efficiency and loading capacity for the two compounds. Loading efficiency describes the fraction of the starting drug successfully incorporated into the carrier, whereas loading capacity refers to how much drug the final micelle material can hold. The authors further report that the co-loaded micelles remained stable under physiological conditions, an important requirement because premature disassembly in blood could release the drugs before they reach their intended destination.

The formulation was then tested against two triple-negative breast cancer cell lines in vitro. According to the study, the presence of both drugs in the POx carrier did not eliminate paclitaxel’s cytotoxic activity. In parallel experiments, the micelles displayed bactericidal activity against F. nucleatum, indicating that the antibacterial compound remained biologically available after incorporation into the polymeric structure. These experiments establish that co-encapsulation did not obviously neutralize either payload. They do not, however, prove that the particles selectively accumulate in human tumors, eradicate bacteria in patients or improve survival compared with standard paclitaxel and antibiotic treatment. Cell cultures and bacterial assays lack the complex blood flow, immune responses, extracellular matrix and oxygen gradients found in living tumors, so the results represent an early proof of feasibility rather than evidence of clinical effectiveness.

The team also examined tolerability in mice and found that the POx/PTX/MB micelles were well tolerated at pharmacologically relevant doses. That finding is encouraging because combining a cytotoxic drug with an antimicrobial agent can raise concerns about overlapping toxicity, altered metabolism and unintended effects on beneficial microorganisms. A nanocarrier could potentially change where and when each drug is released, but it could also introduce new variables, including accumulation in organs, interactions with immune cells and changes in pharmacokinetics. The study’s abstract does not report that the formulation cured tumors or reduced intratumoral bacterial burden in the animals; its animal result is specifically described as tolerability. Detailed questions about distribution, release rates, dose optimization and therapeutic benefit will therefore require further experiments in tumor-bearing models.

The choice of poly(2-oxazoline) reflects a broader effort to develop adaptable carriers for difficult-to-formulate medicines. POx polymers can be engineered by changing their chemical composition, block lengths and hydrophobicity, allowing researchers to tune micelle formation and drug interactions. Earlier work has shown that drugs can influence the shape of POx assemblies, causing transitions between spherical and elongated, worm-like structures. Such morphology can affect how particles move through the bloodstream and how they interact with cells. In the present study, the researchers used an amphiphilic triblock POx platform to accommodate two chemically distinct agents. That flexibility may be valuable for combination therapy, but it also makes manufacturing consistency essential: a future clinical product would need tightly controlled particle size, composition, drug ratio, stability and release behavior from batch to batch.

The work arrives as scientists increasingly investigate the tumor microbiome as a contributor to cancer biology rather than a passive collection of bystanders. Bacteria may reside between tumor cells, inside malignant cells or in specialized niches shaped by oxygen deprivation, immune suppression and altered nutrient availability. Targeting them could complement chemotherapy, immunotherapy or radiation, but indiscriminate antimicrobial treatment might also disrupt normal microbial communities and select for resistance. The researchers’ dual-purpose micelles offer a way to concentrate two established types of therapy in one nanoscale package, potentially reducing the need for separate delivery schedules and exposing bacteria and cancer cells to treatment within the same microenvironment. Before that promise can be tested in people, studies will need to determine whether F. nucleatum is present at clinically meaningful levels in specific breast tumors, whether its removal changes treatment response and whether the formulation improves efficacy without adding unacceptable toxicity. For now, the results suggest a provocative new direction: in some cancers, the most effective drug may need to target the tumor and its microscopic passengers together.

Subject of Research: Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate against triple-negative breast cancer cells and tumor-associated Fusobacterium nucleatum

Article Title: Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment

Article References: Holden, A., Hutsell, H., Palchak, L. et al. “Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment.” Biomedical Microdevices 28, 55 (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00834-w

Keywords: polymeric micelles, poly(2-oxazoline), paclitaxel, metronidazole benzoate, triple-negative breast cancer, tumor microbiome, Fusobacterium nucleatum, nanomedicine